283 related articles for article (PubMed ID: 25314063)
1. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study.
Sinn M; Denkert C; Striefler JK; Pelzer U; Stieler JM; Bahra M; Lohneis P; Dörken B; Oettle H; Riess H; Sinn BV
Br J Cancer; 2014 Nov; 111(10):1917-23. PubMed ID: 25314063
[TBL] [Abstract][Full Text] [Related]
2. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.
Sinn M; Sinn BV; Striefler JK; Lindner JL; Stieler JM; Lohneis P; Bischoff S; Bläker H; Pelzer U; Bahra M; Dietel M; Dörken B; Oettle H; Riess H; Denkert C
Ann Oncol; 2014 May; 25(5):1025-32. PubMed ID: 24562449
[TBL] [Abstract][Full Text] [Related]
3. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
Sinn M; Riess H; Sinn BV; Stieler JM; Pelzer U; Striefler JK; Oettle H; Bahra M; Denkert C; Bläker H; Lohneis P
Eur J Cancer; 2015 Aug; 51(12):1546-54. PubMed ID: 26049689
[TBL] [Abstract][Full Text] [Related]
4. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
[TBL] [Abstract][Full Text] [Related]
5. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
[TBL] [Abstract][Full Text] [Related]
6. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
[TBL] [Abstract][Full Text] [Related]
7. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma.
Wang LM; Silva MA; D'Costa Z; Bockelmann R; Soonawalla Z; Liu S; O'Neill E; Mukherjee S; McKenna WG; Muschel R; Fokas E
Oncotarget; 2016 Jan; 7(4):4183-94. PubMed ID: 26716653
[TBL] [Abstract][Full Text] [Related]
9. Comment on: α-smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study.
Sahin IH; Uzunparmak B
Br J Cancer; 2015 May; 112(11):1838. PubMed ID: 25602961
[No Abstract] [Full Text] [Related]
10.
Sinn M; Sinn BV; Treue D; Keilholz U; Damm F; Schmuck R; Lohneis P; Klauschen F; Striefler JK; Bahra M; Bläker H; Bischoff S; Pelzer U; Oettle H; Riess H; Budczies J; Denkert C
Clin Cancer Res; 2020 Jul; 26(14):3732-3739. PubMed ID: 32234756
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
Diana A; Wang LM; D'Costa Z; Azad A; Silva MA; Soonawalla Z; Allen P; Liu S; McKenna WG; Muschel RJ; Fokas E
Oncotarget; 2016 Nov; 7(45):72819-72832. PubMed ID: 27637082
[TBL] [Abstract][Full Text] [Related]
12. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment.
Striefler JK; Sinn M; Pelzer U; Jühling A; Wislocka L; Bahra M; Sinn BV; Denkert C; Dörken B; Oettle H; Riess H; Bläker H; Lohneis P
Pathol Res Pract; 2016 Aug; 212(8):726-34. PubMed ID: 27461834
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer.
Klein F; Bahra M; Schirmeier A; Al-Abadi H; Pratschke J; Pelzer U; Oettle H; Striefler J; Riess H; Sinn M
J Surg Oncol; 2015 Jul; 112(1):66-71. PubMed ID: 26193339
[TBL] [Abstract][Full Text] [Related]
14. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Xie H; Lin J; Thomas DG; Jiang W; Liu X
Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
[TBL] [Abstract][Full Text] [Related]
15. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
[TBL] [Abstract][Full Text] [Related]
16. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.
Kim R; Tan A; Lai KK; Jiang J; Wang Y; Rybicki LA; Liu X
Cancer; 2011 Jul; 117(14):3126-34. PubMed ID: 21264835
[TBL] [Abstract][Full Text] [Related]
17. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
Richards NG; Rittenhouse DW; Freydin B; Cozzitorto JA; Grenda D; Rui H; Gonye G; Kennedy EP; Yeo CJ; Brody JR; Witkiewicz AK
Ann Surg; 2010 Sep; 252(3):499-505; discussion 505-6. PubMed ID: 20739850
[TBL] [Abstract][Full Text] [Related]
18. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.
Xie H; Jiang W; Xiao SY; Liu X
J Histochem Cytochem; 2013 Feb; 61(2):148-55. PubMed ID: 23124118
[TBL] [Abstract][Full Text] [Related]
19. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.
Boone BA; Bahary N; Zureikat AH; Moser AJ; Normolle DP; Wu WC; Singhi AD; Bao P; Bartlett DL; Liotta LA; Espina V; Loughran P; Lotze MT; Zeh HJ
Ann Surg Oncol; 2015 Dec; 22(13):4402-10. PubMed ID: 25905586
[TBL] [Abstract][Full Text] [Related]
20. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
Takano S; Togawa A; Yoshitomi H; Shida T; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Tomonaga T; Nomura F; Miyazaki M
Ann Surg Oncol; 2008 Nov; 15(11):3157-68. PubMed ID: 18712570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
